Lucid Diagnostics priced its underwritten public stock offering at $1.00 per share, successfully raising approximately $18 million in gross proceeds (yielding roughly $16.8 million in net working capital). This strategic financing round included significant capital participation from institutional investors and corporate insiders, designed to fund ongoing commercial expansion, clinical adoption initiatives, and general corporate operations.